Division of Hematology Oncology, Center for Clinical AIDS Research and Education, University of California Los Angeles, Los Angeles, California 90095, USA.
Curr Opin Oncol. 2011 Sep;23(5):475-81. doi: 10.1097/CCO.0b013e328349c233.
HIV-associated multicentric Castleman disease (HIV MCD) is a rare lymphoproliferative disorder, the incidence of which appears to be increasing in the highly active antiretroviral therapy era. Current knowledge of the disease is limited and this review will discuss what is known about the pathophysiology, diagnosis, management, and prognosis of HIV MCD.
HIV MCD has been shown to be associated with infection with human herpesvirus-8. Vascular endothelial growth factor and the cytokine interleukin-6 (IL-6) are also thought to play a role in the pathogenesis of MCD. Currently, rituximab is often used alone or in combination with chemotherapy for treatment of MCD. Novel monoclonal antibodies targeting IL-6 and the IL-6 receptor are also being studied for the management of this disease.
Because HIV MCD is an uncommon diagnosis, comprehensive clinical studies have not been done, and understanding of the disease is incomplete. Further studies are needed to make definitive conclusions regarding optimal treatment of HIV MCD.
HIV 相关多中心 Castleman 病（HIV-MCD）是一种罕见的淋巴组织增生性疾病，在高效抗逆转录病毒治疗时代，其发病率似乎有所增加。目前对该疾病的了解有限，因此本文将讨论 HIV-MCD 的发病机制、诊断、治疗和预后。
HIV-MCD 已被证实与人类疱疹病毒-8 感染相关。血管内皮生长因子和细胞因子白细胞介素-6（IL-6）也被认为在 MCD 的发病机制中起作用。目前，利妥昔单抗通常单独使用或与化疗联合用于治疗 MCD。针对 IL-6 和 IL-6 受体的新型单克隆抗体也正在研究用于该疾病的治疗。
由于 HIV-MCD 是一种罕见的诊断，尚未进行全面的临床研究，因此对该疾病的了解并不完整。需要进一步的研究来对 HIV-MCD 的最佳治疗方法做出明确的结论。
